Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.
- Record FY26 revenue of $4.45 million
- Australian wholesale revenue up 45% to $2.62 million
- AI audio licensing agreement with OPTEK enters commercial production
- Auracast rollout expands in retirement living and education
- Statutory loss narrows to $1.3 million with improved cash flow
Record Revenue Growth Anchored by Australian Wholesale Surge
Audeara Limited (ASX:AUA) posted a milestone fiscal year ending June 2026, with group revenue climbing to approximately $4.45 million, up from $3.79 million the prior year. The standout driver was a 45% leap in Australian wholesale revenue to $2.62 million, buoyed by strong demand from established audiology partners and the largest individual wholesale purchase order in the company’s history.
This growth underscores the strength of Audeara’s domestic clinical distribution network, which remains a core pillar of its diversified business model. The wholesale channel not only delivers immediate sales but also serves as a conduit for introducing personalised listening technologies to consumers who may not yet require traditional hearing aids.
AI Licensing with OPTEK Advances to Commercial Production
Audeara’s AUA Technology division, which licenses proprietary software and audio-processing algorithms, marked a significant commercial milestone by executing a chip-level AI audio licensing agreement with OPTEK Microelectronics Co., Ltd. This partnership enables Audeara’s AI-driven noise reduction and speech enhancement technologies to be embedded directly into semiconductor platforms.
At the reporting date, two OPTEK customer programs had progressed into commercial production, validating Audeara’s scalable fee-per-chip licensing model and positioning the company for broader adoption across consumer audio and hearing health devices. The financial impact of these programs will unfold as customers complete validation and ramp production.
International Expansion Through Licensing and Distribution
Beyond Australia, Audeara expanded its footprint in Asia through multiple initiatives. In China, the company progressed a licensing deal with Eastech, achieving regulatory certification for a hearing aid incorporating Audeara technology and commencing manufacturing. An initial order for 1,000 licence keys was received, with products set to be sold via established e-commerce and hearing-health channels.
In Taiwan, Audeara deepened its relationship with Clinico Inc., launching three additional white-label programs including Auracast-enabled devices and partner-branded accessories. Meanwhile, a new distribution agreement with Eyear System Inc. opened the Japanese market for Audeara’s Auracast-enabled audio transceivers and broadcasters, with joint efforts underway on certification and marketing.
Auracast Deployments Expand Accessibility in Community Settings
Audeara advanced its Auracast™ shared-listening ecosystem, which allows audio transmission to multiple devices without traditional Bluetooth pairing. A flagship rollout with Bolton Clarke began in Queensland, targeting 43 retirement villages to enhance audio accessibility in communal spaces. This initiative exemplifies practical applications of Auracast technology to support social participation and wellbeing.
Further, Audeara secured exclusive Australian rights from Shokz Health Global Limited for a customised open-ear listening solution targeting children with learning and listening challenges. Developed in collaboration with Ear Science Institute Australia, the product is designed for educational settings and aims to improve classroom engagement through clearer sound access.
Financial Performance and Cash Flow Improvements
While the Group recorded a statutory loss after tax of $1.3 million, this represented a marked improvement from the $1.78 million loss in FY25. Net operating cash flow improved significantly to a negative $0.39 million, including two consecutive quarters of positive cash flow, reflecting disciplined expenditure and working-capital management.
Research and development investment remained substantial at $3.04 million, with an expected R&D Tax Incentive refund of approximately $1.32 million supporting ongoing innovation in AI audio processing, personalised listening, embedded software, and Auracast-enabled products.
Capital Raise and Strategic Outlook
Post-year-end, Audeara secured firm commitments for a $1.26 million placement to fund inventory, licensing programs, and cash flow sustainability. The capital raise, structured in two tranches with shareholder approval pending for the second, aligns with the company’s focus on converting its expanding commercial pipeline into recurring revenue.
Looking ahead, the Group prioritises scaling production and repeat orders across Australian wholesale, OPTEK programs, Clinico white-label products, and the China hearing-aid initiative. Continued expansion of Auracast infrastructure and the ShokzHear education solution also feature prominently in FY27 plans.
Material Risks and Governance
Audeara’s Board remains vigilant on key risks including customer concentration; where the top four customers accounted for 78% of revenue; regulatory approvals, and access to financial resources to fund growth. The company’s governance framework and risk management policies aim to mitigate these challenges while supporting disciplined capital allocation.
The remuneration report reveals a stable leadership team with aligned incentives, including share-based payments to executive directors and the Chair, reinforcing commitment to long-term value creation.
As Audeara navigates the complex interplay of technology licensing, product manufacturing, and market expansion, the timing of revenue recognition from new international programs and Auracast deployments will be critical to watch. The company’s ability to convert its broadening commercial base into sustainable cash flow remains the defining challenge for the next phase.
Bottom Line?
Audeara’s FY26 results highlight tangible progress in revenue growth and technology commercialisation, but the path to sustained profitability hinges on scaling production and managing partner-driven timing risks.
Questions in the middle?
- How quickly will OPTEK’s AI audio licensing programs scale beyond initial commercial production?
- Can Auracast deployments in retirement and education sectors translate into consistent recurring revenue?
- What impact will the $1.26 million placement have on funding product launches and working capital?